Evidence map›Paper›PMID 32372249›Full record

ArticleMolecular diversity2021

Design, antihuman immunodeficiency activity and molecular docking studies of synthesized 2-aryl and 2-pyrimidinyl pyrrolidines.

Sahak P Gasparyan, Ashot H Martirosyan, Marina V Alexanyan, Gohar K Harutyunyan, Garri V Chilingaryan, Steve Coats, Raymond F Schinazi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular diversity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.0field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sahak P GasparyanScientific and Technological Centre of Organic and Pharmaceutical Chemistry, Institute of Fine Organic Chemistry, National Academy of Sciences of RA, Azatutyan Avenue 26, 0014, Yerevan, Republic of Armenia. g_sahak@yahoo.com.ORCID http://orcid.org/0000-0003-2341-724X
Ashot H MartirosyanScientific and Technological Centre of Organic and Pharmaceutical Chemistry, Institute of Fine Organic Chemistry, National Academy of Sciences of RA, Azatutyan Avenue 26, 0014, Yerevan, Republic of Armenia.
Marina V AlexanyanScientific and Technological Centre of Organic and Pharmaceutical Chemistry, Institute of Fine Organic Chemistry, National Academy of Sciences of RA, Azatutyan Avenue 26, 0014, Yerevan, Republic of Armenia.
Gohar K HarutyunyanScientific and Technological Centre of Organic and Pharmaceutical Chemistry, Institute of Fine Organic Chemistry, National Academy of Sciences of RA, Azatutyan Avenue 26, 0014, Yerevan, Republic of Armenia.
Garri V ChilingaryanDepartment of Medical Biochemistry and Biotechnology, Institute of Biomedicine and Pharmacy, Russian-Armenian Niversity, Hovsep Emin Street 123, 0051, Yerevan, Republic of Armenia.
Steve CoatsCenter for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, 1760 Haygood Drive, Atlanta, GA, 30322, USA.
Raymond F SchinaziCenter for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, 1760 Haygood Drive, Atlanta, GA, 30322, USA.
Institute of Fine Organic Chemistry of Scientific - Technological Center of Organic and Pharmaceutical Chemistry · AMEmory University · USRussian-Armenian University · AM

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Civilian Research and Development Foundation (CRDF) ARB2-2701-YE-05NIAID NIH HHS P30 AI050409NIH HHS P30-AI-050409
6 · The paper itself

Abstract

A series of thirty-one new compounds were synthesized and evaluated for their anti-HIV-1 and cytotoxicity activity. Of these, twelve were found to be inhibitors of HIV replications in primary human lymphocytes with median effective concentration (EC

Indexed as

Anti-HIV AgentsDrug DesignHIV-1Molecular Docking SimulationPyrrolidinesHIV InfectionsHIV Reverse TranscriptaseHumansStructure-Activity RelationshipVirus ReplicationAnti-HIV AgentsHIV Reverse TranscriptasePyrrolidines2-Aryl pyrrolidinesAnti-HIV-1 activityBinding energyDocking studiesPyrimidinyl pyrrolidines

Identifiers

PMID32372249
PMCPMC7720369
OpenAlexW3021651541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.